13.1 The Well-Woman Visit & Cervical Cancer Screening
Key Takeaways
- Cervical cancer screening is not recommended before age 21 regardless of sexual debut, because transient HPV infection is common and treatment of benign changes causes preterm birth.
- From 21 to 29 years, cytology alone every 3 years is recommended and HPV testing is not, because high HPV prevalence drives unnecessary colposcopy.
- From 30 to 65 years, acceptable strategies are cytology every 3 years, primary high-risk HPV testing every 5 years, or co-testing every 5 years.
- Screening may stop after 65 with 3 consecutive negative cytology results or 2 consecutive negative co-tests in the past 10 years, the most recent within 5 years.
- A history of CIN 2 or higher requires continued surveillance for at least 25 years, even beyond age 65 or after total hysterectomy.
The annual well-woman visit represents the cornerstone of preventive healthcare in midwifery practice. Grounded in the midwifery model of care, the well-woman encounter transcends episodic symptom management to provide holistic, lifespan-oriented health promotion, shared clinical decision-making, and evidence-based disease prevention. For the certified nurse-midwife (CNM), mastering the national screening guidelines established by the United States Preventive Services Task Force (USPSTF), the American Society for Colposcopy and Cervical Pathology (ASCCP), the American College of Obstetricians and Gynecologists (ACOG), and the Advisory Committee on Immunization Practices (ACIP) is essential for clinical excellence and success on the AMCB certification examination.
Well-Woman Annual Visit Architecture & Lifespan Preventive Care
The annual preventive visit is structured around a comprehensive clinical history, targeted health behavior counseling, an individualized, trauma-informed physical examination, and age-specific diagnostic screening. Rather than relying on a rigid, one-size-fits-all examination, modern guidelines emphasize personalized care tailored to age, reproductive life goals, medical and family pedigree, and individualized risk factors.
Core Components of the Well-Woman History
- Gynecologic & Menstrual History: Menarche, cycle interval (normal 24 to 38 days), cycle regularity, duration of bleeding (normal ≤8 days), volume of flow, presence of severe dysmenorrhea, molimina symptoms, and date of the last menstrual period (LMP). In perimenopausal and postmenopausal women, evaluate bleeding patterns, vasomotor symptoms, and genitourinary symptoms of menopause.
- Obstetric History: Detailed GP (Gravida/Para) and FPAL (Full-term, Preterm, Abortions [spontaneous/induced], Living children) score, route of birth, gestational age at birth, infant birth weights, and obstetric complications (preeclampsia, gestational diabetes, postpartum hemorrhage).
- Sexual History (The "5 Ps"):
- Partners: Number, gender(s), and duration of sexual partnerships.
- Practices: Specific sexual activities (vaginal, anal, oral), barrier device utilization, and presence of sexual pain or dysfunction.
- Prevention of STIs: Consistent condom use, history of pre-exposure prophylaxis (PrEP) if indicated.
- Past History of STIs: Prior episodes of Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, herpes simplex virus (HSV), trichomoniasis, or pelvic inflammatory disease (PID).
- Pregnancy Intentions: One Key Question ("Would you like to become pregnant in the next year?") to anchor reproductive life planning and contraceptive or pre-conception counseling.
- Psychosocial & Safety Screenings:
- Intimate Partner Violence (IPV): Universal screening for all adolescent and adult women utilizing validated tools such as the HITS screening instrument (Hurt, Insult, Threaten, Scream) or direct, private questioning.
- Mental Health: Universal screening for major depressive disorder using the Patient Health Questionnaire-2 (PHQ-2), escalating to the PHQ-9 if positive; screening for generalized anxiety using the GAD-7.
- Substance Use: Universal screening using the Screening, Brief Intervention, and Referral to Treatment (SBIRT) framework for tobacco, alcohol (AUDIT-C), cannabis, and illicit substances.
- Social Determinants of Health (SDOH): Assessment of housing stability, food insecurity, economic security, transportation access, and systemic barriers to care.
The Physical Examination: Evidence-Based Indications
Historically, an annual bimanual pelvic examination, speculum examination, and clinical breast examination were considered mandatory components of every well-woman visit. Current evidence-based guidelines from the USPSTF, ACOG, and the American College of Physicians (ACP) clarify that routine, asymptomatic screening pelvic examinations in non-pregnant, non-symptomatic individuals do not reduce morbidity or mortality from ovarian, uterine, or other pelvic malignancies and are associated with false-positive findings, unnecessary surgery, and patient anxiety.
- Indications for Pelvic Examination: Cervical cancer screening at designated age intervals, evaluation of abnormal uterine bleeding, investigation of acute or chronic pelvic pain, evaluation of pelvic organ prolapse or incontinence, suspected pelvic masses, evaluation of vulvovaginal symptoms or infectious discharge, and prior to insertion of an intrauterine device (IUD).
- Asymptomatic Shared Decision-Making: For asymptomatic women aged 21 and older presenting for an annual visit when cervical cancer screening is not due, the decision to perform an internal bimanual pelvic examination should be made collaboratively between the woman and her midwife through shared decision-making.
Cervical Cancer Screening Guidelines: USPSTF & ASCCP Framework
Cervical cancer screening is one of the most successful public health initiatives in modern medicine, reducing cervical cancer incidence and mortality by more than 75%. Cervical carcinogenesis is almost universally driven by persistent infection with oncogenic high-risk Human Papillomavirus (hrHPV) genotypes. Over 90% of incident HPV infections in young individuals are transient and cleared effectively by cell-mediated host immunity within 12 to 24 months without causing neoplastic progression.
Cervical Screening Intervals Across the Lifespan
| Age Group | Recommended Screening Strategy | Testing Interval | Clinical Rationale & High-Yield Caveats |
|---|---|---|---|
| <21 Years | NO SCREENING RECOMMENDED | None | Screening is strictly not recommended regardless of age at sexual debut or risk behaviors. High rate of transient HPV infections that resolve spontaneously. Treatment of benign cytologic changes causes cervical incompetence and preterm birth. |
| 21 to 29 Years | Cervical Cytology Alone (Pap smear) | Every 3 Years | Liquid-based or conventional cytology alone. hrHPV testing (primary or co-testing) is NOT recommended in this cohort because high HPV prevalence triggers excessive colposcopies and biopsies without reducing cancer incidence. |
| 30 to 65 Years | Option 1: Cervical Cytology Alone<br/>Option 2: High-Risk HPV (hrHPV) Alone<br/>Option 3: Co-Testing (Cytology + hrHPV) | Cytology: Every 3 Years<br/>hrHPV Alone: Every 5 Years<br/>Co-Testing: Every 5 Years | All three strategies are endorsed by USPSTF, ACOG, and ASCCP. Primary hrHPV alone every 5 years with an FDA-approved assay provides superior sensitivity compared to cytology alone and avoids redundant co-testing costs. |
| >65 Years | Discontinue Screening (if adequate prior negative screening documented) | Cessation | Criteria for cessation: 3 consecutive negative cytology results OR 2 consecutive negative co-tests/hrHPV tests within the past 10 years, with the most recent test performed within the past 5 years. |
| Post-Hysterectomy | Discontinue Screening (if cervix removed and no high-grade history) | Cessation | If total hysterectomy (cervix removed) for benign indications and no history of CIN 2+ in past 25 years. If supracervical hysterectomy (cervix intact), continue routine screening. |
[!IMPORTANT] The 25-Year CIN 2+ Exception: Women with a documented history of treated or untreated high-grade precancerous cervical lesions (CIN 2, CIN 3, or adenocarcinoma in situ [AIS]) must continue routine age-appropriate cervical screening for a minimum of 25 years after diagnosis and treatment, even if this surveillance extends beyond 65 years of age or occurs following total hysterectomy (vaginal cuff cytology every 3 years).
A 33-year-old presents for an annual visit. She is asymptomatic, her last co-test 4 years ago was negative, and she has no history of cervical dysplasia. She asks whether she needs a pelvic examination today. What is the most appropriate response?